A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer

Clinical trial NCT00567190 · COMPLETED

Trial details

NCT number: NCT00567190
Sponsor: Genentech, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Breast Cancer

Start date: 2008-02-12
Primary completion: 2011-05-13
Enrollment: 808

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.